JP2000121306A5
(enExample )
2006-06-15
JP2003528207A5
(enExample )
2007-11-01
JP2001513504A5
(enExample )
2008-08-21
AU2002234545A1
(en )
2002-06-18
Pharmaceutical preparation in the form of a suspension comprising an acid-labileactive ingredient
JP2000271573A5
(enExample )
2004-10-28
JP2000235403A5
(enExample )
2005-04-07
JP2003517586A5
(enExample )
2006-11-09
EE200200385A
(et )
2003-12-15
Alfa-(2,4-disulfofenüül)-N-tert-butüülnitrooni jaselle farmatseutiliselt vastuvõetavate soolade uus valmistamise meetod
JPH1025251A5
(enExample )
2005-01-20
JP2001316679A5
(enExample )
2006-09-21
JPH02127194U
(enExample )
1990-10-19
JPH0432974U
(enExample )
1992-03-17
JPS635204Y2
(enExample )
1988-02-12
Act
2000
Knowledge of
JPH01157141U
(enExample )
1989-10-30
AU6181600A
(en )
2001-02-19
Guanosine triphosphate-binding protein coupled receptors, genes thereof and production and use of the same
JPH0369923U
(enExample )
1991-07-12
JPH0415934U
(enExample )
1992-02-10
Tamanini
1999
The Role of the FMRI Protein Involved in Fragle X-Syndrome
JPH0357966U
(enExample )
1991-06-05
JPH0391509U
(enExample )
1991-09-18
JPH0399956U
(enExample )
1991-10-18
JPH0413585U
(enExample )
1992-02-04
JPS6441255U
(enExample )
1989-03-13
JPS63151745U
(enExample )
1988-10-05